CD8A and neoplasm: This molecular reprogramming enabled two key outcomes: (1) robust recruitment of effector T cells to tumor niches via chemokine gradients, and (2) efficient cross-presentation of tumor antigens via MHC class I molecules to prime polyclonal CD8+ T cell responses.